Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan)

Invest Radiol. 2007 Feb;42(2):139-45. doi: 10.1097/01.rli.0000253505.88945.d5.


Objectives: Nephrogenic systemic fibrosis (NSF) is a rare acquired disorder that was first recognized in 1997. Presented is a retrospective review of 6 cases of NSF diagnosed by skin biopsy in our institution during the past 4 years and their relationship to gadodiamide exposure.

Methods and results: Patient age ranged from 23 to 71 years. The onset of symptoms consistent with NSF was between 19 days and 2 months after gadodiamide exposure. Five patients had severe renal impairment and started dialysis around the period of gadodiamide exposure (1 day before the 37 days after contrast administration). The sixth patient had a clotted access at the time of a contrast-enhanced magnetic resonance venogram and was hence not being adequately dialyzed. The dose of gadodiamide ranged from 16 to 40 mL (0.11 to 0.36 mmol/kg). Despite having normal serum bicarbonate, 5 of the 6 patients had an elevated anion gap metabolic acidosis.

Conclusions: In our 6 patients, all had either failing native or transplant kidneys at the time of gadodiamide exposure. The development of NSF was temporally related to gadodiamide injection, suggesting as the etiology dechelation of the agent and thus emphasizing the need for change in clinical practice.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Aged
  • Contrast Media / adverse effects*
  • Female
  • Fibrosis
  • Gadolinium DTPA / adverse effects*
  • Humans
  • Magnetic Resonance Imaging / adverse effects*
  • Male
  • Middle Aged
  • Renal Insufficiency / complications*
  • Renal Insufficiency / pathology*
  • Skin Diseases / chemically induced*
  • Skin Diseases / pathology*


  • Contrast Media
  • gadodiamide
  • Gadolinium DTPA